Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
RCT
ACE Report #8930
Ace Report Cover Metabolic Disorders

WCO-IOF 2016: Greater BMD increase after 1 year of romosozumab vesus teripratide


Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy

Contributing Authors: J Malouf B Langdahl C Libanati DB Crittenden K Engelke JS Finkelstein HK Genant S Goemaere L Hyldstrup E Jodar-Gimeno TM Keaveny D Kendler P Lakatos J Maddox FE Massari JF Molina MR Ulla A Grauer

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Synopsis

436 postmenopausal women with osteoporosis who had been administered oral bisphosphonate therapy for 3 years prior were randomized in a phase 3 clinical trial to subcutaneous romosozumab or subcutaneous teriparatide. The purpose of this study was to compare the change in bone mineral density after 1 year of treatment between the two groups. Reported results demonstrated a significantly greater inc...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.